Blair William & Co. IL Lowers Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Blair William & Co. IL trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,834 shares of the biotechnology company’s stock after selling 953 shares during the quarter. Blair William & Co. IL’s holdings in BioMarin Pharmaceutical were worth $3,033,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Innealta Capital LLC purchased a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $25,000. BOKF NA acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter valued at $31,000. Quent Capital LLC raised its position in BioMarin Pharmaceutical by 58.9% in the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 145 shares during the period. Jones Financial Companies Lllp acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $43,000. Finally, AM Squared Ltd purchased a new stake in shares of BioMarin Pharmaceutical in the second quarter worth about $66,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on BMRN. Stifel Nicolaus dropped their target price on BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. Barclays reduced their target price on shares of BioMarin Pharmaceutical from $111.00 to $110.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Bank of America dropped their price target on shares of BioMarin Pharmaceutical from $130.00 to $115.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Scotiabank cut their price objective on shares of BioMarin Pharmaceutical from $95.00 to $78.00 and set a “sector perform” rating on the stock in a report on Tuesday, September 17th. Finally, Evercore ISI raised their target price on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, August 6th. Eight analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $98.84.

BioMarin Pharmaceutical Trading Down 1.0 %

BioMarin Pharmaceutical stock opened at $70.69 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.95 and a current ratio of 3.05. BioMarin Pharmaceutical Inc. has a 1 year low of $68.83 and a 1 year high of $99.56. The firm’s 50-day moving average is $85.57 and its 200-day moving average is $84.26. The company has a market cap of $13.42 billion, a P/E ratio of 66.07, a PEG ratio of 1.03 and a beta of 0.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, August 5th. The biotechnology company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.39. The company had revenue of $712.03 million during the quarter, compared to the consensus estimate of $660.51 million. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. On average, equities analysts expect that BioMarin Pharmaceutical Inc. will post 2.4 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.